Skip to main content

clobetasol

Generic: CLOBETASOL PROPIONATE·Brand: BYQLOVI, Byqlovi, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE (EMOLLIENT), CLOBEX, CORMAX, Clobex, Clodan, EMBELINE, EMBELINE E, IMPEKLO, IMPOYZ, Impeklo, Impoyz, OLUX, OLUX E, Olux, TEMOVATE, TEMOVATE E, Temovate, Tovet

clobetasol: 2 clinical trials tracked.

clobetasol evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about clobetasol, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Atopic Dermatitis

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trials (2)

Safety and Efficacy of Topical Bacteriotherapy for Atopic Dermatitis Using Staphylococcus Hominis A9

NCT06504160·Phase 1
Recruiting

Primary endpoint: Time to the first Atopic Dermatitis (AD) flare.

InterventionalRandomizedquadruple86 targetStarted 2025-05Completion 2027-028 sites · United StatesNational Institute of Allergy and Infectious Diseases (NIAID)

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

NCT06120140·Phase 2
Active, not recruiting

Primary endpoint: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment

InterventionalRandomizedopen305 targetStarted 2024-02Completion 2032-0150 sites · Argentina, Brazil, China, United StatesJanssen Research & Development, LLC